• Explore /
  • Poster
  • / The safety and efficacy of transarterial chemoembolization (TACE) + lenvatinib + programmed cell death protein 1 (PD-1) antibody of advanced unresectable hepatocellular carcinoma.

The safety and efficacy of transarterial chemoembolization (TACE) + lenvatinib + programmed cell death protein 1 (PD-1) antibody of advanced unresectable hepatocellular carcinoma.

Abstract Poster

Authors

null

Xiaoyun Zhang

Department of Liver Surgery and Liver Transplantation Center, West China Hospital, Sichuan University, Chengdu, China

Xiaoyun Zhang , Xinrui Zhu , Chang Liu , Wusheng Lu , Qiu Li , Weixia Chen , Zhiping Li , Qiang Lu , Wei Peng , Chuan Li , Lvnan Yan , Jiayin Yang , Tianfu Wen

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

04997850

DOI

10.1200/JCO.2022.40.4_suppl.453

Abstract #

453

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Jinpeng Li

First Author: Claudia A.M. Fulgenzi

First Author: Yunfei Yuan

First Author: Guoliang Shao